Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29181055 | 0.86 | BLM (0.61) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL30833309 | 0.86 | BLM (0.61) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4864377 | 0.81 | PKM (0.76) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4872272 | 0.80 | TACR1 (0.54) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4872760 | 0.80 | TACR1 (0.56) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8320877 | 0.78 | POLB (0.57) | MEN1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL4874741 | 0.74 | MAPT (0.81) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3174823 | 0.73 | MEN1 (0.80) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4865829 | 0.72 | TACR1 (0.57) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1885179 | 0.70 | MEN1 (0.77) | MEN1KMT2AMAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | claimed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1581222-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004060362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | MEN1 1961/4885KMT2A 4237/4885MAPT 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.